Jinhai Medical Technology (02225) is included in the Hang Seng Composite Index and is expected to become the standard for Hong Kong stocks

Zhitong Finance App learned that on August 21, Hang Seng Index Company announced the results of the Hang Seng Index series of quarterly reviews up to June 30, 2026. Among them, Jinhai Medical Technology (02225) was included in the Hang Seng Composite Index. Changes in the Hang Seng Composite Index will be implemented after the market closes on September 4 (Friday) and will take effect on September 7 (Monday). At that time, the Shanghai and Shenzhen Stock Exchange will adjust the scope of investment targets of Hong Kong Stock Connect accordingly. Jinhai Medical Technology may be transferred to the Hong Kong Stock Connect because it meets a range of standards including market value and liquidity.

On August 3, Jinhai Medical Technology issued an announcement announcing the appointment of Mr. Ma Chengdong as the Group's Chief Marketing Officer, effective from August 3, 2026, for an initial term of one year. According to the announcement, Ma Chengdong will be mainly responsible for the marketing strategy, market access, academic promotion, sales and channel operation of the Group's products, and supervise the commercialization of the Group's medical devices and equipment products.